Simmons & Simmons LLP

General information
Simmons & Simmons LLP
Thierschplatz 6
Lehel Carré
80538 Munich, Bavaria

Contact person: Thomas Gniadek, Partner
Company main phone: +49 (89) 2080776300
Company main fax:  +49 (89) 2080776301
Year founded:2013
Source of foundation:Subsidiary
Name of foundation source:Simmons & Simmons, London
No. of employees: Worldwide:  1500
Corporate description / mission:
Simmons & Simmons LLP operates as an international law firm. The company provides legal advices to asset management and investment funds, energy and infrastructure, financial institutions, life sciences, technology, media, and telecommunications sectors. The firm caters to the aerospace, consumer goods, energy and utilities, financial markets, pharmaceutical and biotechnology, real estate, construction, banking, finance, biotechnology, chemicals, communications, construction, and shipping industries.
State of ownership: Private / independent
Headquarters: HQ: No
  • Professional Services and Consulting
  • Legal services
Business model:
  • Service company
  • Subsidiary
Customer segments:
  • Large biotech & big pharma
  • Small biotech
  • Direct (own sales force)
Collaborations & Clients
Client portfolio (as relevant):

LEO Pharma
„„on its $1bn acquisition of Warner
Chilcott’s dermatology franchise

Ascendis Pharma
„„on its first major deal concerning
its proprietary TransCon Linker and
Hydrogel carrier technology, following
an auction process involving share sale
and licensing structures

R-Pharm Group
„„on the acquisition of a Pfizer production
plant in Germany

Rothschild and J.P.Morgan Cazenove
„„as joint sponsors, and Rothschild
as financial adviser, to BTG plc in
connection with its acquisition of
Biocompatibles International plc

Santen Pharmaceutical
„„on the acquisition of the majority stake
in France-based Novagali Pharma
Shareholders of Specifar
„„on the US$562m acquisition of the
company by Watson Pharmaceuticals

„„on an agreement with Netherlands
based DSM Anti-Infectives, to form
a 50/50 global anti-infectives joint


Amsterdam Molecular Therapeutics
„„ on its successful €14.3m equity raising
Circassia Pharmaceuticals
„„the syndicate of underwriting banks on
Circassia’s £581m IPO on the London
Main Market in March 2014, London’s
largest biotech flotation for decades

„„on the secondary listing of the largest
adult stem cell storage bank in Europe
and its shares on Euronext Amsterdam
by NYSE Euronext (alongside the
company’s listing on AIM)

Kempen & Co and Petercam
„„on the successful €12m equity raising
by Euronext Amsterdam listed biotech
company Pharming Group N.V.

NetScientific plc
„„on its £30m placing and AIM IPO

Union MedTech plc
„„on its acquisition of Rex Bionics Limited
and £25.7m Placing and AIM IPO

Venture Life Group plc
„„on its acquisition of Biokosmes and £5m
Placing and AIM IPO